(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
How to watch 2026 Golden Globe winners like 'One Battle After Another,' 'Adolescence' and 'The Pitt' - 2Police break up illegal chicken slaughter in Germany
- 3Violence 'never part' of break-in plan, court told
- 4Home Plan Tips for Seniors
- 5Triple polar vortex to plunge central and eastern U.S. into Arctic cold through mid-December
- I asked ChatGPT who would win a Golden Globes. Here's what it got right — and totally wrong.
- Gym tied to outbreak of obscure disease that spreads through mist
- Scientists find new clues to why female fertility declines with age
- Israeli archaeologists launch project to trace origins of ancient pottery
- 7 Powerful Techniques to Boost Efficiency with Your Cell Phone: A Far reaching Guide
- Journey through Pages: A Survey of \Plunging into Scholarly Universes\
- A throat bone settles it - Nanotyrannus was not a juvenile T. rex
- 10 Asian Countries Perfect for Solo Female Travelers
- Kaiser Permanente affiliates to pay $556 million to resolve US claims alleging Medicare fraud
